ScholarLens Back to search
2022•JAMARequires access

Risks to the 340B Drug Pricing Program

Anastasia G. Daifotis

Open publisher page 0 citations

Abstract

To the Editor As a supporter of the 340B Drug Pricing Program and its originally intended mission, I read the recent Viewpoint1 entitled “Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability” with great interest.

About this research paper

What this paper is about

To the Editor As a supporter of the 340B Drug Pricing Program and its originally intended mission, I read the recent Viewpoint1 entitled “Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability” with great interest.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To the Editor As a supporter of the 340B Drug Pricing Program and its originally intended mission, I read the recent Viewpoint1 entitled “Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability” with great interest.

Key concepts: Medicine, Drug pricing, Drug, Actuarial science, Pharmacology, Business

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Risks to the 340B Drug Pricing Program — Research Paper | ScholarLens